CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Eli Lilly and 3M have stopped a clinical trial of their jointly developed genital herpes treatment Resiquimod because preliminary data showed that the drug was not effective, The Wall Street Journal reports. Earlier Phase II trials showed that the drug was safe and well-tolerated, but preliminary data from a Phase III human trial showed that the compound was not as effective as expected in prompting the immune system into attacking herpes virus in the body, in preventing herpes outbreaks, or in helping to prevent people carrying the virus from infecting others. The companies plan to further analyze the trial data to determine whether to conduct further studies of the compound.
From our Sponsors
Most Popular
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
Idris Elba and Mo Abudu Launch Programs to Invest in African Film and Television Talent
March 16 2023 4:38 PM
Chasten Buttigieg Claps Back at Pence Over Transportation Secretary's Parental Leave
March 16 2023 4:26 PM